collection

Addiction treatment

shared collection
479 papers 1000+ followers
By Christopher Cook, BA,CADC, SAP Addiction professional. LPC, CADC, CRNP- student, Interventionist, project manager, owner, Director, eval/refer for SUDs/Eating D/o's
https://read.qxmd.com/read/31663029/current-advances-in-research-in-treatment-and-recovery-nicotine-addiction
#1
REVIEW
Judith J Prochaska, Neal L Benowitz
The health harms of combusted tobacco use are undeniable. With market and regulatory pressures to reduce the harms of nicotine delivery by combustion, the tobacco product landscape has diversified to include smokeless, heated, and electronic nicotine vaping products. Products of tobacco combustion are the main cause of smoking-induced disease, and nicotine addiction sustains tobacco use. An understanding of the biology and clinical features of nicotine addiction and the conditioning of behavior that occurs via stimuli paired with frequent nicotine dosing, as with a smoked cigarette, is important for informing pharmacologic and behavioral treatment targets...
October 2019: Science Advances
https://read.qxmd.com/read/31689444/pathoetiology-and-pathophysiology-of-borderline-personality-role-of-prenatal-factors-gut-microbiome-mu-and-kappa-opioid-receptors-in-amygdala-pfc-interactions
#2
REVIEW
George Anderson
The pathoetiology and pathophysiology of borderline personality disorder (BPD) have been relatively under-explored. Consequently, no targetted pharmaceutical treatments or preventative interventions are available. The current article reviews the available data on the biological underpinnings of BPD, highlighting a role for early developmental processes, including prenatal stress and maternal dysbiosis, in BPD pathoetiology. Such factors are proposed to drive alterations in the infant's gut microbiome, in turn modulating amygdala development and the amygdala's two-way interactions with other brain regions...
November 2, 2019: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://read.qxmd.com/read/31695678/orexins-as-novel-therapeutic-targets-in-inflammatory-and-neurodegenerative-diseases
#3
REVIEW
Alain Couvineau, Thierry Voisin, Pascal Nicole, Valérie Gratio, Catalina Abad, Yossan-Var Tan
Orexins [orexin-A (OXA) and orexin-B (OXB)] are two isoforms of neuropeptides produced by the hypothalamus. The main biological actions of orexins, focused on the central nervous system, are to control the sleep/wake process, appetite and feeding, energy homeostasis, drug addiction, and cognitive processes. These effects are mediated by two G protein-coupled receptor (GPCR) subtypes named OX1R and OX2R. In accordance with the synergic and dynamic relationship between the nervous and immune systems, orexins also have neuroprotective and immuno-regulatory (i...
2019: Frontiers in Endocrinology
https://read.qxmd.com/read/31481723/safety-and-neurochemical-profiles-of-acute-and-sub-chronic-oral-treatment-with-agmatine-sulfate
#4
David H Bergin, Yu Jing, Gail Williams, Bruce G Mockett, Hu Zhang, Wickliffe C Abraham, Ping Liu
Agmatine (decarboxylated arginine) exerts numerous central nervous system (CNS) dependent pharmacological effects and may potentially modulate altered neurochemistry seen in neurological disorders. In preclinical studies, injection has been the predominant route of systemic administration. However, a significant translational step would be the use of oral agmatine treatment at therapeutic doses and better understanding of L-arginine metabolic profiles in the CNS post-treatment. The present study systematically investigated the tolerability, safety and brain-plasma neurochemistry following daily oral agmatine sulfate treatment (via gavage) to wild-type (WT) mice up to 900 mg/kg for one week (Experiment 1) or WT and APPswe/PS1ΔE9 transgenic (Tg) mice at 300 mg/kg for fifteen weeks (Experiment 2)...
September 3, 2019: Scientific Reports
https://read.qxmd.com/read/31493433/agmatine-reverses-ethanol-consumption-in-rats-evidences-for-an-interaction-with-imidazoline-receptors
#5
Brijesh G Taksande, Shreesha Nambiar, Shardha Patil, Milind J Umekar, Manish M Aglawe, Nandkishor R Kotagale
Alcohol is one of the most widely abused recreational drugs, largely linked with serious health and social concerns. However, the treatment options for alcohol-use disorders have limited efficacy and exhibit a range of adverse drug reactions. Large numbers of preclinical studies have projected a biogenic amine, agmatine as a promising potential treatment option for drug addiction, including alcoholism. In the present study, administration of agmatine (20-40 mg/kg, i.p.) resulted in significant inhibition of ethanol self-administration in the right p-VTA in operant conditioning paradigm...
November 2019: Pharmacology, Biochemistry, and Behavior
https://read.qxmd.com/read/31518574/antidepressant-like-effects-of-agmatine-and-nos-inhibitors-in-chronic-unpredictable-mild-stress-model-of-depression-in-rats-the-involvement-of-nlrp-inflammasomes
#6
Ceren Sahin Ozkartal, Erdem Tuzun, Cem Ismail Kucukali, Canan Ulusoy, Murat Giris, Feyza Aricioglu
Innate immunity activation in the central nervous system (CNS) is known to contribute to the development of depression through NOD-like receptors containing pyrin domain 3 (NLRP3) inflammasome assembly. Furthermore, administration of agmatine (AGM), a nitric oxide synthase (NOS) inhibitor, reverses stress-induced NLRP3 inflammasome activation in rats. We examined the effects of chronically-administered nitric oxide (NO) pathway modulating drugs on NLRP1/3-mediated neuroinflammatory responses and depressive-like behaviors in chronic unpredictable mild stress (CUMS) depression model of rats...
December 15, 2019: Brain Research
https://read.qxmd.com/read/31520686/inhibitory-influence-of-agmatine-in-ethanol-withdrawal-induced-depression-in-rats-behavioral-and-neurochemical-evidences
#7
Niyamat Chimthanawala, Shruti Patil, Rishabh Agrawal, Nandkishor R Kotagale, Milind J Umekar, Brijesh G Taksande
Although ethanol withdrawal depression is one of the prominent reasons for its reinstatement and dependence, its neurochemical basis is not clearly understood. Present study investigated the role of agmatinergic system in ethanol withdrawal-induced depression using forced swim test (FST) in rats. Chronic exposure of animals to ethanol for 21 days and its abrupt withdrawal produced depression like behavior as evidenced by increased immobility time in FST, compared to the pair-fed control animals. The ethanol withdrawal-induced depression was significantly attenuated by agmatine (20-40 μg/rat, i...
September 11, 2019: Alcohol
https://read.qxmd.com/read/31629205/altered-plasma-levels-of-arginine-metabolites-in-depression
#8
Arisoy Ozden, Halaris Angelos, Aricioglu Feyza, Wild Elizabeth, Piletz John
L-Arginine pathway metabolites appear to play differential roles in the pathogenesis of major depressive disorder (MDD). Studies have revealed an antidepressant and anxiolytic effect of agmatine and putrescine. Possible mechanisms of these effects include inhibition of nitric oxide synthase and N-methyl-D-aspartate receptors. The present study sought to determine whether MDD is associated with altered levels of arginine metabolites and whether these metabolites are associated with depression, anxiety and stress severity...
October 7, 2019: Journal of Psychiatric Research
https://read.qxmd.com/read/29966280/sales-and-advertising-channels-of-new-psychoactive-substances-nps-internet-social-networks-and-smartphone-apps
#9
REVIEW
Cristina Miliano, Giulia Margiani, Liana Fattore, Maria Antonietta De Luca
In the last decade, the trend of drug consumption has completely changed, and several new psychoactive substances (NPS) have appeared on the drug market as legal alternatives to common drugs of abuse. Designed to reproduce the effects of illegal substances like cannabis, ecstasy, cocaine, or ketamine, NPS are only in part controlled by UN conventions and represent an emerging threat to global public health. The effects of NPS greatly differ from drug to drug and relatively scarce information is available at present about their pharmacology and potential toxic effects...
June 29, 2018: Brain Sciences
https://read.qxmd.com/read/30634521/non-medical-use-of-novel-synthetic-opioids-a-new-challenge-to-public-health
#10
REVIEW
Barbara Lovrecic, Mercedes Lovrecic, Branko Gabrovec, Marco Carli, Matteo Pacini, Angelo G I Maremmani, Icro Maremmani
Background : In the last decade there has been a progressive increase in the use of new psychoactive substances (NPSs) that are not yet under international control. In particular, novel synthetic opioids (NSOs) have reappeared on the recreational drug market in the last few years. As a result, the use of NSOs has increased rapidly. This poses an emerging and demanding challenge to public health. Aim : To raise awareness among clinicians and other professionals about NPSs, especially NSOs, to summarize current knowledge about pharmacological properties, forms of NSO on the market, pattern of use, effects and consequences of use...
January 9, 2019: International Journal of Environmental Research and Public Health
https://read.qxmd.com/read/31050051/drug-dealing-on-facebook-snapchat-and-instagram-a-qualitative-analysis-of-novel-drug-markets-in-the-nordic-countries
#11
Jakob Demant, Silje Anderdal Bakken, Atte Oksanen, Helgi Gunnlaugsson
INTRODUCTION AND AIMS: Internet use has changed drug dealing over the past decade owing to the emergence of darknet services. Yet, little is known about drug dealing in public online services. This study reports findings from a Nordic comparative study on social media drug dealing. It is the first in-depth study on the increase of digitally mediated drug dealing outside the cryptomarkets. DESIGN AND METHODS: A qualitative study using online ethnography and semi-structured interviews...
May 2019: Drug and Alcohol Review
https://read.qxmd.com/read/31097357/postmortem-concentrations-of-the-synthetic-opioid-u-47700-in-26-fatalities-associated-with-the-drug
#12
Helena Fels, Stefanie Lottner-Nau, Tanja Sax, Gabriele Roider, Matthias Graw, Volker Auwärter, Frank Musshoff
Most recently, the synthetic opioid U-47700 has emerged on the illicit drug market and is sold on the Internet as a "research chemical". Its structure is closely related to the synthetic opioid AH-7921. U-47700 is a μ-opioid receptor agonist with a potency of approximately 7.5 times that of morphine. In this study, postmortem concentrations of U-47700 are presented in 26 fatalities which occurred between April 2016 and August 2017 in the southern part of Germany. In 18 of these cases, quantitative analyses of U-47700 were carried out in femoral blood, heart blood, liver, urine, vitreous humor, pericardial fluid, and gastric content...
August 2019: Forensic Science International
https://read.qxmd.com/read/18720674/ecstasy-analogues-found-in-cacti
#13
Jan G Bruhn, Hesham R El-Seedi, Nikolai Stephanson, Olof Beck, Alexander T Shulgin
Human interest in psychoactive phenethylamines is known from the use of mescaline-containing cacti and designer drugs such as Ecstasy. From the alkaloid composition of cacti we hypothesized that substances resembling Ecstasy might occur naturally. In this article we show that lophophine, homopiperonylamine and lobivine are new minor constituents of two cactus species, Lophophora williamsii (peyote) and Trichocereus pachanoi (San Pedro). This is the first report of putatively psychoactive phenethylamines besides mescaline in these cacti...
June 2008: Journal of Psychoactive Drugs
https://read.qxmd.com/read/30670513/benefits-and-harms-of-pregabalin-in-the-management-of-neuropathic-pain-a-rapid-review-and-meta-analysis-of-randomised-clinical-trials
#14
Igho J Onakpoya, Elizabeth T Thomas, Joseph J Lee, Ben Goldacre, Carl J Heneghan
OBJECTIVE: To assess the benefits and harms of pregabalin in the management of neuropathic pain. DESIGN: Rapid review and meta-analysis of phase III, randomised, placebo-controlled trials. PARTICIPANTS: Adults aged 18 years and above with neuropathic pain defined according to the International Association for the Study of Pain criteria. INTERVENTIONS: Pregabalin or placebo. PRIMARY AND SECONDARY OUTCOME MEASURES: Our primary outcomes were pain (as measured using validated scales) and adverse events...
January 21, 2019: BMJ Open
https://read.qxmd.com/read/31495691/the-effects-of-cannabis-cannabinoids-and-their-administration-routes-on-pain-control-efficacy-and-safety-a-systematic-review-and-network-meta-analysis
#15
Karma Rabgay, Neti Waranuch, Nathorn Chaiyakunapruk, Ratree Sawangjit, Kornkanok Ingkaninan, Piyameth Dilokthornsakul
OBJECTIVES: To determine the effects of cannabis, cannabinoids, and their administration routes on pain and adverse euphoria events. DATA SOURCES: A systematic search was performed in PubMed, ScienceDirect, ClincalTrials.gov, Scopus, Cochrane Library, and Embase from inception until June 2017. STUDY SELECTION: Randomized controlled trials investigating the effects of cannabis or cannabinoids on pain reduction. DATA EXTRACTION: Two reviewers extracted and assessed the quality of studies by means of Cochrane risk of bias...
September 5, 2019: Journal of the American Pharmacists Association: JAPhA
https://read.qxmd.com/read/31591935/a-neurobehavioral-approach-to-addiction-implications-for-the-opioid-epidemic-and-the-psychology-of-addiction
#16
Antoine Bechara, Kent C Berridge, Warren K Bickel, Jose A Morón, Sidney B Williams, Jeffrey S Stein
Two major questions about addictive behaviors need to be explained by any worthwhile neurobiological theory. First, why do people seek drugs in the first place? Second, why do some people who use drugs seem to eventually become unable to resist drug temptation and so become "addicted"? We will review the theories of addiction that address negative-reinforcement views of drug use (i.e., taking opioids to alleviate distress or withdrawal), positive-reinforcement views (i.e., taking drugs for euphoria), habit views (i...
October 2019: Psychological Science in the Public Interest: a Journal of the American Psychological Society
https://read.qxmd.com/read/31605587/is-opioid-free-general-anesthesia-more-superior-for-postoperative-pain-versus-opioid-general-anesthesia-in-laparoscopic-cholecystectomy
#17
Marija Toleska, Aleksandar Dimitrovski
INTRODUCTION: Opioid-free anesthesia (OFA) is a new anesthesiological technique, where the giving of opioids (fentanyl) is avoided in the intra- and post-operative period. This leads to reduction in the opioid-related side effects and lower pain scores in the postoperative period. MATERIALS AND METHODS: In this randomized, single-blind clinical study, 60 patients scheduled for elective laparoscopic cholecystectomy were enrolled. Half of them (30 patients) received general balanced anesthesia with fentanyl (F group-FG), and the half received opioid-free general anesthesia (OFA group-OFAG)...
October 1, 2019: Prilozi (Makedonska Akademija Na Naukite i Umetnostite. Oddelenie za Medicinski Nauki)
https://read.qxmd.com/read/31288397/potential-adverse-drug-events-and-drug-drug-interactions-with-medical-and-consumer-cannabidiol-cbd-use
#18
REVIEW
Joshua D Brown, Almut G Winterstein
Cannabidiol (CBD) is ubiquitous in state-based medical cannabis programs and consumer products for complementary health or recreational use. CBD has intrinsic pharmacologic effects and associated adverse drug events (ADEs) along with the potential for pharmacokinetic and pharmacodynamic drug-drug interactions (DDIs). Given CBD use among patients with complex conditions and treatment regimens, as well as its expanded consumer use, awareness of potential safety issues with CBD is needed. Prescribing information for federally approved products containing CBD were reviewed...
July 8, 2019: Journal of Clinical Medicine
https://read.qxmd.com/read/31393863/vital-signs-pharmacy-based-naloxone-dispensing-united-states-2012-2018
#19
Gery P Guy, Tamara M Haegerich, Mary E Evans, Jan L Losby, Randall Young, Christopher M Jones
BACKGROUND: The CDC Guideline for Prescribing Opioids for Chronic Pain recommends considering prescribing naloxone when factors that increase risk for overdose are present (e.g., history of overdose or substance use disorder, opioid dosages ≥50 morphine milligram equivalents per day [high-dose], and concurrent use of benzodiazepines). In light of the high numbers of drug overdose deaths involving opioids, 36% of which in 2017 involved prescription opioids, improving access to naloxone is a public health priority...
August 9, 2019: MMWR. Morbidity and Mortality Weekly Report
https://read.qxmd.com/read/31547093/current-understanding-of-methamphetamine-associated-metabolic-changes-revealed-by-the-metabolomics-approach
#20
REVIEW
Minjeong Kim, Won-Jun Jang, Rupa Shakya, Boyeon Choi, Chul-Ho Jeong, Sooyeun Lee
Metabolomics is a powerful tool used in the description of metabolic system perturbations caused by diseases or abnormal conditions, and it usually involves qualitative and/or quantitative metabolome determination, accompanied by bioinformatics assessment. Methamphetamine is a psychostimulant with serious abuse potential and due to the absence of effective pharmacotherapy and a high recurrence potential, methamphetamine addiction is a grave issue. Moreover, its addiction mechanisms remain unclear, probably due to the lack of experimental models that reflect personal genetic variances and environmental factors determining drug addiction occurrence...
September 20, 2019: Metabolites
label_collection
label_collection
2001
1
2
2019-10-19 01:34:49
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"